A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy

Jennifer N. Bennett, Michael D. Blough, Ian Mitchell, Lyle Galloway, Ravinder Bains
doi: https://doi.org/10.1101/2023.04.12.23288325

Article Information

doi 
https://doi.org/10.1101/2023.04.12.23288325
History 
  • April 19, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Jennifer N. Bennett1,†,*,
  2. Michael D. Blough1,†,
  3. Ian Mitchell2,
  4. Lyle Galloway3,4 and
  5. Ravinder Bains1,5,6,†
  1. 1ATMA Journey Centers Inc., Calgary, Alberta, Canada
  2. 2Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada
  3. 3Department of Oncology, University of Calgary, Calgary, Alberta, Canada
  4. 4Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada
  5. 5Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  6. 6Short Stay Unit, Peter Lougheed Centre, Calgary, Alberta, Canada
  1. ↵*Correspondence:
    Jennifer Bennett jennifer{at}atmajourney.com

  1. ↵† These authors contributed equally and share first authorship

Back to top
Posted April 19, 2023.
Download PDF
Data/Code
Email
A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
Jennifer N. Bennett, Michael D. Blough, Ian Mitchell, Lyle Galloway, Ravinder Bains
medRxiv 2023.04.12.23288325; doi: https://doi.org/10.1101/2023.04.12.23288325
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area